Engineering T cell therapies for cancer and chronic diseases | @Columbia Institute for Cell Engineering and Therapy (CICET)
Joined April 2017
- Tweets 484
- Following 265
- Followers 1,116
- Likes 1,672
12 Photos and videos
Max Mamonkin retweeted
28 Nov 2024
IL15 increases the expansion of CAR T cells and induces antitumor responses in patients with GPC3 solid tumors (i.e. liver cancer).
nature.com/articles/s41586-0…
5
37
142
14,616
Max Mamonkin retweeted
19 Oct 2024
A cell intrinsic NKG2A/C switch receptor to overcome the critical HLA-E checkpoint. Fun collaboration with the Michel Sadelain lab. Michelle Sætersmoen, Ivan Kotchetkov, @LambertoTR @CoE_PRIMA @UniOslo_MED @Oslounivsykehus @CIM_Sweden
18 Oct 2024
Online Now: Targeting HLA-E-overexpressing cancers with a NKG2A/C switch receptor dlvr.it/TFV5VC
5
16
51
6,157
Max Mamonkin retweeted
7 Oct 2024
I am very pleased to announce the work I did as a graduate student in the labs of Crystal Mackall and Everett Meyer has been published in Nature Communications, open access! nature.com/articles/s41467-0…
2
11
82
9,863
Max Mamonkin retweeted
30 Sep 2024
Columbia welcomes CAR-T pioneer Michel Sadelain, MD, PhD, as the inaugural director of the new Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative at the Herbert Irving Comprehensive Cancer Center.
➡️columbiamed.link/3zCR9iI
ALT Columbia welcomes Michel Sadelain, MD, PhD, Director of the Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative in the Herbert Irving Comprehensive Cancer Center.
5
28
194
36,431
Max Mamonkin retweeted
22 Sep 2024
Recruiting faculty to the Dept of Molecular and Cellular Biology at Baylor College of Medicine in Houston, TX! Recruiting broadly in cancer and cell biology. Submit by October 1, 2024, for full review. #cellbio @BCMhouston
bcm.edu/departments/molecula…
jobs.sciencecareers.org/job/…
1
93
145
24,855
Max Mamonkin retweeted
24 Sep 2024
Preprint alert 🚨
Up to 90% CAR knock-in rates in primary human T cells - without drug enhancers? 🧐
Single-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells
biorxiv.org/content/10.1101/…
🧵👇
10
28
133
19,968
Max Mamonkin retweeted
16 Sep 2024
My department (MIT Biological Engineering) is hiring at the Assistant Professor level! We are looking for someone in immunology/immunotherapy/immune engineering, broadly defined. be.mit.edu/about/open-facult…
5
50
146
32,892
7 Sep 2024
Great step forward in humanized mouse models. Using iPSC-derived CD34 iHSC which engraft and produce human multi-lineage progeny in immunodeficient NBSGW mice
nature.com/articles/s41587-0…
1
4
22
1,773
5 Sep 2024
An interesting POC of T cell therapy in CNS injury models: autoreactive MOG-specific T cells infiltrate the lesion and suppress tissue damage, counter-intuitively in part via IFNg secretion. But you have to act fast.
nature.com/articles/s41586-0…
1
2
19
1,087
3 Sep 2024
Excellent results with autologous CD7-PEBL CART in T-ALL from Singapore and Rome nature.com/articles/s41591-0…
3
16
38
4,256
Max Mamonkin retweeted
15 Aug 2024
The genomic basis of childhood T-lineage acute lymphoblastic leukaemia | Nature nature.com/articles/s41586-0…
2
8
847
13 Aug 2024
T cells express a ton of CD5, so why CD5 CAR T cells don't kill each other? Turns out, they completely degrade CD5 protein and thus evade fratricide. Unique mechanism unveiled in a mechanistic study - and PhD thesis work - by Royce Ma:
cell.com/cell-reports-medici…
3
23
100
7,548
Max Mamonkin retweeted
19 Jul 2024
Congrats to the now Dr. @_ruchipatel
for the publication of her PhD thesis in @SciImmunology. We show here that CD5 deletion enhances CART immunotherapy in multiple solid and liquid cancer models. @PennMedicine @RuellaLab science.org/doi/10.1126/scii…
5
28
120
9,264
Max Mamonkin retweeted
9 Jul 2024
Are all hybrid antigen receptors as easy to design as CARs? Definitely not! doi.org/10.1158/2159-8290.CD… (1/4)
3
8
41
7,229
Max Mamonkin retweeted
8 Jul 2024
Comprehensive thread highlighting our most recent work now out in @CellStemCell describing a novel approach to increase persistence of allogeneic cell therapy products. Work led by amazing @QuirinHammer and @KarloPerica. @CoE_PRIMA, @Oslounivsykehus @UniOslo_MED @karolinskainst
8 Jul 2024
Happy to share the final work from my post-doc with @MalmbergLab published in @CellStemCell today cell.com/cell-stem-cell/full…
extensive 15-post-🧵 below
4
29
2,605
27 Jun 2024
Limiting institutional overhead on NIH grants?
27 Jun 2024
Paragraph tucked into House NIH funding bill to limit indirects makes research $ go further and attacks administrative bloat at wealthy colleges. Proposal caps indirects at 30% rather than reimbursing at a school's actual overhead rate. Current policy encourages wasteful spending at universities; this bill creates a powerful incentive to control costs.
via @stuartbuck1
1
891
7 Jun 2024
The answer is NO. Here's a patient with neuroblastoma who was treated 18 years ago with GD2.CAR T cells at Baylor @CAGTHouston and still remains in remission. We need more of these stories.
researchsquare.com/article/r…
4 Jun 2024
Matt Rea was treated with CD19 CART cells back in 2010 at Baylor @CAGTHouston and has been cancer-free since then, for 14 years. The CAR-T were made from his twin brother. Is he the longest surviving CAR-T patient?
blogs.bcm.edu/2024/06/04/fol…
2
16
62
6,400
4 Jun 2024
Matt Rea was treated with CD19 CART cells back in 2010 at Baylor @CAGTHouston and has been cancer-free since then, for 14 years. The CAR-T were made from his twin brother. Is he the longest surviving CAR-T patient?
blogs.bcm.edu/2024/06/04/fol…
2
17
53
11,061
22 May 2024
Like many disruptive technologies, engineered T-cell therapies follow the Gartner hype cycle. We are approaching the second upward slope.
4
11
81
9,066
Max Mamonkin retweeted
14 May 2024
🚀 Join Our Team at Baylor College of Medicine! 🧬
We’re looking for passionate technician to join our lab at @CAGTHouston. Help us develop innovative and accessible cell therapies for cancer and autoimmunity using genome editing.
Pls RT 🙏
jobs.bcm.edu/job/Research-Te…
14
31
5,538